one8zero8 LLC Acquires Shares of 39,700 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

one8zero8 LLC bought a new position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 39,700 shares of the biotechnology company’s stock, valued at approximately $499,000.

A number of other large investors have also recently modified their holdings of the stock. First Turn Management LLC boosted its position in shares of Rocket Pharmaceuticals by 10.8% during the third quarter. First Turn Management LLC now owns 621,306 shares of the biotechnology company’s stock valued at $11,476,000 after purchasing an additional 60,317 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Rocket Pharmaceuticals during the 3rd quarter valued at $636,000. Jennison Associates LLC grew its position in shares of Rocket Pharmaceuticals by 33.2% in the 3rd quarter. Jennison Associates LLC now owns 40,740 shares of the biotechnology company’s stock worth $752,000 after buying an additional 10,162 shares during the period. Intech Investment Management LLC bought a new position in shares of Rocket Pharmaceuticals in the 3rd quarter worth about $527,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Rocket Pharmaceuticals by 3.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 569,814 shares of the biotechnology company’s stock valued at $10,524,000 after acquiring an additional 20,322 shares during the period. Institutional investors own 98.39% of the company’s stock.

Rocket Pharmaceuticals Trading Up 3.1 %

NASDAQ:RCKT opened at $8.76 on Monday. The company has a market cap of $934.08 million, a PE ratio of -3.19 and a beta of 1.03. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The company has a 50 day simple moving average of $10.22 and a two-hundred day simple moving average of $13.94. Rocket Pharmaceuticals, Inc. has a 12 month low of $8.06 and a 12 month high of $28.67.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.06. Research analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on RCKT shares. The Goldman Sachs Group decreased their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. Wedbush initiated coverage on Rocket Pharmaceuticals in a research note on Monday, December 30th. They set an “outperform” rating and a $32.00 price objective for the company. Needham & Company LLC cut their target price on Rocket Pharmaceuticals from $52.00 to $42.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Chardan Capital lowered their price target on Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating for the company in a research report on Friday, February 28th. Finally, Scotiabank increased their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.00.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.